We are live on ! Find out more
AIM

Alerce Investment Management Portfolio holdings

AUM $56.8M
1-Year Est. Return 31.17%
This Fund
S&P 500
This Quarter Est. Return
-33.97%
1 Year Est. Return
+31.17%
3 Year Est. Return
+25.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$51M
AUM Growth
-$44.1M
Cap. Flow
-$11.6M
Cap. Flow %
-22.76%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$3.11M

Top Sells

Rank Stock Value
1
AKBA icon
Akebia Therapeutics
AKBA
+$9.22M
2
RNTX
Rein Therapeutics
RNTX
+$5.51M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
1
Annexon
ANNX
$834M
$36.3M 71.13%
7,406,024
– –
AKBA icon
2
Akebia Therapeutics
AKBA
$354M
$5.86M 11.49%
5,747,906
-7,457,213
-56% -$9.22M
AMWL icon
3
American Well
AMWL
$180M
$3.4M 6.67%
523,786
– –
VRNA
4
DELISTED
Verona Pharma
VRNA
$3.08M 6.04%
+213,000
New +$3.11M
WHWK
5
Whitehawk Therapeutics
WHWK
$190M
$2.38M 4.67%
1,630,830
– –
RNTX
6
Rein Therapeutics
RNTX
$63.1M
– –
-830,466
Closed -$5.51M

Similar funds

CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
AFA
Atlas Financial Advisors Oroville, California $64.1M AUM 8.36% 1-Year Est. Return
MCC
Maiden Cove Capital Cape Elizabeth, Maine $65.4M AUM
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
MC
Meketa Capital Westwood, Massachusetts $44.6M AUM
OAM
Origin Asset Management London, United Kingdom $43.5M AUM 31.63% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
JCP
Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

Alerce Investment Management's Q2 2024 Portfolio in Review

As of Q2 2024, Alerce Investment Management held 6 positions worth $51M, down 46% from $95.1M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Alerce Investment Management withdrew a net $11.6M in Q2 2024, closing 1 position and reducing 1 holding. Its most notable exit was Rein Therapeutics, an estimated $5.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Alerce Investment Management opened a new position in Verona Pharma worth $3.08M.

  • Alerce Investment Management's largest Q2 2024 buy was Verona Pharma: 213,000 shares worth $3.08M.
  • Alerce Investment Management's biggest Q2 2024 reduction was Akebia Therapeutics, cutting an estimated $9.22M.
  • Alerce Investment Management fully exited Rein Therapeutics in Q2 2024, selling an estimated $5.51M.
  • Alerce Investment Management's ten largest holdings make up 100% of its $51M portfolio in Q2 2024.
  • Alerce Investment Management opened 1 new position and closed 1 in Q2 2024.
  • Alerce Investment Management's portfolio value fell 46% quarter-over-quarter to $51M.

Based on Alerce Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.